140 related articles for article (PubMed ID: 15352163)
21. Using multi-objective computational design to extend protein promiscuity.
Suarez M; Tortosa P; Garcia-Mira MM; Rodríguez-Larrea D; Godoy-Ruiz R; Ibarra-Molero B; Sanchez-Ruiz JM; Jaramillo A
Biophys Chem; 2010 Mar; 147(1-2):13-9. PubMed ID: 20034725
[TBL] [Abstract][Full Text] [Related]
22. A large-scale computational approach to drug repositioning.
Li YY; An J; Jones SJ
Genome Inform; 2006; 17(2):239-47. PubMed ID: 17503396
[TBL] [Abstract][Full Text] [Related]
23. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
[TBL] [Abstract][Full Text] [Related]
24. Disruption of protein-protein interactions: towards new targets for chemotherapy.
Loregian A; Palù G
J Cell Physiol; 2005 Sep; 204(3):750-62. PubMed ID: 15880642
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of protein-protein interactions using designed molecules.
Wilson AJ
Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
[TBL] [Abstract][Full Text] [Related]
26. Strategies for targeting protein-protein interactions with synthetic agents.
Yin H; Hamilton AD
Angew Chem Int Ed Engl; 2005 Jul; 44(27):4130-63. PubMed ID: 15954154
[TBL] [Abstract][Full Text] [Related]
27. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
28. Domain-based small molecule binding site annotation.
Snyder KA; Feldman HJ; Dumontier M; Salama JJ; Hogue CW
BMC Bioinformatics; 2006 Mar; 7():152. PubMed ID: 16545112
[TBL] [Abstract][Full Text] [Related]
29. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
30. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
Heilker R; Wolff M; Tautermann CS; Bieler M
Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
[TBL] [Abstract][Full Text] [Related]
31. BlockMaster: partitioning protein kinase structures using normal-mode analysis.
Shudler M; Niv MY
J Phys Chem A; 2009 Jul; 113(26):7528-34. PubMed ID: 19485335
[TBL] [Abstract][Full Text] [Related]
32. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
Andrews G; Jones C; Wreggett KA
Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting protein-protein interactions using designed molecules.
Zhao L; Chmielewski J
Curr Opin Struct Biol; 2005 Feb; 15(1):31-4. PubMed ID: 15718130
[TBL] [Abstract][Full Text] [Related]
34. Between a rock and a hard place?
Whitty A; Kumaravel G
Nat Chem Biol; 2006 Mar; 2(3):112-8. PubMed ID: 16484997
[TBL] [Abstract][Full Text] [Related]
35. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
[TBL] [Abstract][Full Text] [Related]
36. Emerging classes of protein-protein interaction inhibitors and new tools for their development.
Pagliaro L; Felding J; Audouze K; Nielsen SJ; Terry RB; Krog-Jensen C; Butcher S
Curr Opin Chem Biol; 2004 Aug; 8(4):442-9. PubMed ID: 15288255
[TBL] [Abstract][Full Text] [Related]
37. The structural basis of allosteric regulation in proteins.
Laskowski RA; Gerick F; Thornton JM
FEBS Lett; 2009 Jun; 583(11):1692-8. PubMed ID: 19303011
[TBL] [Abstract][Full Text] [Related]
38. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.
Johnson MP; Nisenbaum ES; Large TH; Emkey R; Baez M; Kingston AE
Biochem Soc Trans; 2004 Nov; 32(Pt 5):881-7. PubMed ID: 15494040
[TBL] [Abstract][Full Text] [Related]
39. Screening for positive allosteric modulators of biological targets.
Groebe DR
Drug Discov Today; 2006 Jul; 11(13-14):632-9. PubMed ID: 16793532
[TBL] [Abstract][Full Text] [Related]
40. Docking interactions in protein kinase and phosphatase networks.
Reményi A; Good MC; Lim WA
Curr Opin Struct Biol; 2006 Dec; 16(6):676-85. PubMed ID: 17079133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
